Madrigal Pharmaceuticals Inc
$ 519.61
-0.89%
10 Apr - close price
- Market Cap 12,027,425,000 USD
- Current Price $ 519.61
- High / Low $ 526.50 / 507.54
- Stock P/E N/A
- Book Value 26.39
- EPS -12.85
- Next Earning Report 2026-05-07
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.16 %
- ROE -0.43 %
- 52 Week High 615.00
- 52 Week Low 265.00
About
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic and liver diseases. The company is headquartered in West Conshohocken, Pennsylvania.
Analyst Target Price
$668.57
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-19 | 2025-10-29 | 2025-08-05 | 2025-05-05 | 2025-02-26 | 2024-10-31 | 2024-08-07 | 2024-05-07 | 2024-02-28 | 2023-11-06 | 2023-08-08 | 2023-05-09 |
| Reported EPS | -2.57 | -4.9555 | -1.9 | -3.32 | -2.71 | -4.92 | -7.1 | -7.38 | -5.68 | -5.34 | -4.69 | -4.23 |
| Estimated EPS | -0.6039 | -3.36 | -3.63 | -6.28 | -4.1246 | -6.91 | -7.53 | -6.28 | -5.28 | -4.93 | -4.58 | -4.94 |
| Surprise | -1.9661 | -1.5955 | 1.73 | 2.96 | 1.4146 | 1.99 | 0.43 | -1.1 | -0.4 | -0.41 | -0.11 | 0.71 |
| Surprise Percentage | -325.5671% | -47.4851% | 47.6584% | 47.1338% | 34.2967% | 28.7988% | 5.7105% | -17.5159% | -7.5758% | -8.3164% | -2.4017% | 14.3725% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-07 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -3.62 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MDGL
2026-04-10 12:39:24
Madrigal Pharmaceuticals (MDGL) has seen significant share price volatility but appears undervalued based on two valuation methods. A Discounted Cash Flow (DCF) analysis estimates the stock to be 71.3% undervalued at approximately $1,809.70 per share compared to its current price of $519.75. Additionally, the P/S ratio suggests the shares are trading below their fair value.
2026-04-09 21:09:44
Madrigal Pharmaceuticals (MDGL) has seen significant share price volatility, with a 65.6% return over the past year. Despite recent declines, two valuation models, Discounted Cash Flow (DCF) and Price to Sales (P/S) ratio, suggest the stock is undervalued. The DCF analysis indicates a potential intrinsic value of $1,809.70 per share, significantly higher than its current trading price of around $519.75.
2026-04-09 04:39:24
Madrigal Pharmaceuticals (MDGL) is currently valued at approximately US$12.2 billion and is trading at a discount to the analyst price target of US$668.57, suggesting it is undervalued. The company's lead drug, Rezdiffra, has strong growth expectations and a new U.S. patent extending exclusivity to 2045, which is anticipated to drive sustained revenue growth and margin expansion. However, risks include heavy reliance on Rezdiffra and potential competition from GLP-1 drugs.
2026-04-08 18:40:13
Madrigal Pharmaceuticals (MDGL) is currently valued at US$12.2 billion and is trading below the analyst target price of US$668.57, suggesting it is undervalued. The company's valuation gap is supported by the rapid uptake and extended patent protection of Rezdiffra until 2045, which promises sustained revenue growth and margin expansion. Despite the positive outlook from Rezdiffra, investors are cautioned to consider risks such as heavy reliance on the drug and potential competition from GLP-1 alternatives.
2026-04-08 06:04:00
Madrigal Pharmaceuticals has granted equity awards, totaling 8,079 restricted stock units, to 20 new non-executive employees. These inducement awards, vesting over four years, are a strategy to attract and retain talent in the competitive biopharmaceutical industry. The move signifies Madrigal's dedication to expanding its workforce and advancing its lead MASH drug candidate, Rezdiffra.
2026-04-07 22:34:00
Madrigal Pharmaceuticals granted equity awards to 20 new non-executive employees as inducement awards under its 2025 Inducement Plan. These 8,079 time-based restricted stock units, vesting over four years, aim to attract and retain top talent in the competitive biopharmaceutical industry. The awards align employee interests with shareholder success and were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
